PAI-1过表达促进食管鳞癌细胞的侵袭和迁移

doi:10.16288/j.yczz.19-334

遗传 ›› 2020, Vol. 42 ›› Issue (3): 287-295.doi: 10.16288/j.yczz.19-334

PAI-1过表达促进食管鳞癌细胞的侵袭和迁移

王迪, 杨荔艳, 刘奏, 余竟, 张敏杰, 张钰, 蔡岩, 徐昕, 郝佳洁(), 王明荣()

国家癌症中心/国家肿瘤临床医学研究中心, 中国医学科学院北京协和医学院肿瘤医院肿瘤精准医学研究中心, 分子肿瘤学国家重点实验室,北京 100021

收稿日期:2019-12-31 修回日期:2020-02-12 出版日期:2020-03-20 发布日期:2020-02-27
通讯作者: 郝佳洁,王明荣 E-mail:hjj8173@126.com;wangmr2015@126.com
作者简介:王迪,硕士研究生,专业方向：肿瘤遗传学。E-mail: 15604011202@163.com
基金资助:
国家自然科学基金项目编号(81520108023);中国医学科学院医学与健康科技创新工程项目编号(2019-I2M-1-003);中国医学科学院医学与健康科技创新工程项目编号(2016-I2M-3-007);北京市科技新星项目资助编号(Z171100001117017)

PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells

Wang Di, Yang Liyan, Liu Zou, Yu Jing, Zhang Minjie, Zhang Yu, Cai Yan, Xu Xin, Hao Jiajie(), Wang Mingrong()

State Key Laboratory of Molecular Oncology, Center for Cancer Precision Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2019-12-31 Revised:2020-02-12 Online:2020-03-20 Published:2020-02-27
Contact: Hao Jiajie,Wang Mingrong E-mail:hjj8173@126.com;wangmr2015@126.com
Supported by:
Supported by the National Natural Science Foundation of China No(81520108023);CAMS Innovation Fund for Medical Sciences Nos(2019-I2M-1-003);CAMS Innovation Fund for Medical Sciences Nos(2016-I2M-3-007);Beijing Nova Program No(Z171100001117017)

摘要/Abstract

摘要：

食管癌是常见的恶性肿瘤之一。由SERPINE1基因编码的纤溶酶原激活物抑制因子1 (plasminogen activator inhibitor-1, PAI-1)已被报道在多种类型癌症患者的肿瘤组织中存在高表达并参与癌症进展。为探讨PAI-1蛋白在食管鳞癌中的作用及其分子机制,本研究首先利用Western blot实验和酶联免疫吸附实验(enzyme linked immunosorbent assay, ELISA)检测各食管鳞癌细胞系中PAI-1的表达和分泌水平,结果显示,PAI-1高表达的食管鳞癌细胞系分泌至细胞外的PAI-1水平相对较高。进一步选取PAI-1表达及分泌水平均较高的KYSE150和KYSE450细胞系作为研究模型,通过siRNA(小干扰RNA)瞬时转染和Transwell实验证实敲降SERPINE1可显著抑制食管鳞癌KYSE150和KYSE450细胞的侵袭和迁移。同时,构建了慢病毒介导的SERPINE1稳定敲降细胞株KYSE150和KYSE450,将SERPINE1稳定敲降的细胞培养基中外源加入PAI-1蛋白进行 Transwell回复实验,结果表明PAI-1过表达可增强食管鳞癌细胞的侵袭和迁移能力。体内实验结果显示,降低PAI-1表达可显著抑制食管鳞癌细胞的成瘤和肺转移能力。分子水平检测表明PAI-1过表达可激活AKT和ERK信号通路,免疫共沉淀(co-immunoprecipitation, Co-IP)实验结果进一步显示PAI-1可能与膜受体LRP1 (LDL receptor related protein 1)存在相互作用。上述研究结果表明,PAI-1可能通过与LRP1相互作用进而促进食管鳞癌细胞的侵袭和迁移。

关键词: PAI-1, 食管鳞癌, 侵袭, 迁移

Abstract:

Esophageal squamous cell carcinoma (ESCC) is one of the most common cancers worldwide. Plasminogen activator inhibitor-1 (PAI-1), encoded by SERPINE1, is highly expressed in various types of tumor tissues, which contributes to cancer progression. The present study explored the role and underlying mechanisms of PAI-1 in ESCC. We found that the PAI-1 protein was extracellularly secreted more from ESCC cells with high PAI-1 expression using Western blotting and enzyme linked immunosorbent assay (ELISA). Knockdown of SERPINE1 expression significantly inhibited the invasion and migration of ESCC KYSE150 and KYSE450 cell lines, which could be restored when adding exogenous human recombinant PAI-1 into the culture medium of the cells stably expressing SERPINE1 shRNA. In vivo experiments showed that SERPINE1 knockdown significantly inhibited xenograft growth and lung metastasis of ESCC cells. Molecular analysis demonstrated that PAI-1 activated AKT and ERK signaling pathways. Co-immunoprecipitation (Co-IP) assays identified that PAI-1 may interact with the membrane receptor LDL receptor related protein 1 (LRP1). These results indicated that overexpression of PAI-1, through interacting with LRP1, might enhance invasion and migration of ESCC cells as well as promote ESCC progression.

Key words: PAI-1, ESCC, invasion, migration

王迪, 杨荔艳, 刘奏, 余竟, 张敏杰, 张钰, 蔡岩, 徐昕, 郝佳洁, 王明荣. PAI-1过表达促进食管鳞癌细胞的侵袭和迁移[J]. 遗传, 2020, 42(3): 287-295.

Wang Di, Yang Liyan, Liu Zou, Yu Jing, Zhang Minjie, Zhang Yu, Cai Yan, Xu Xin, Hao Jiajie, Wang Mingrong. PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells[J]. Hereditas(Beijing), 2020, 42(3): 287-295.

图/表 6

图1

图2

图3

图4

图5

图6

参考文献 34

[1]	Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, Jemal A, Yu XQ, He J . Cancer statistics in China, 2015. CA Cancer J Clin, 2016,66(2):115-132.
[2]	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin, 2015,65(2):87-108.
[3]	McMahon B, Kwaan HC . The plasminogen activator system and cancer. Pathophysiol Haemost Thromb, 2008,36(3-4):184-194.
[4]	Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ . PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Mol Cancer Res, 2014,12(3):322-334.
[5]	Xu J, Zhang WW, Tang L, Chen WW, Guan XX . Epithelial-mesenchymal transition induced PAI-1 is associated with prognosis of triple-negative breast cancer patients. Gene, 2018,670:7-14.
[6]	Zhang WW, Xu J, Fang HH, Tang L, Chen WW, Sun Q, Zhang Q, Yang F, Sun ZJ, Cao LL, Wang YC, Guan XX . Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling. FASEB J, 2018,32(1):276-288.
[7]	Lin X, Lin BW, Chen XL, Zhang BL, Xiao XJ, Shi JS, Lin JD, Chen X . PAI-1/PIAS3/Stat3/miR-34a forms a positive feedback loop to promote EMT-mediated metastasis through Stat3 signaling in Non-small cell lung cancer. Biochem Biophys Res Commun, 2017,493(4):1464-1470.
[8]	Nishioka N, Matsuoka T, Yashiro M, Hirakawa K, Olden K, Roberts JD . Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci, 2012,103(2):228-232.
[9]	Sakakibara T, Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A . Plasminogen activator inhibitor-1 as a potential marker for the malignancy of esophageal squamous cell carcinoma. Clin Cancer Res, 2004,10(4):1375-1378.
[10]	Placencio VR, DeClerck YA. Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing. Cancer Res, 2015,75(15):2969-2974.
[11]	Kubala MH, Punj V, Placencio-Hickok VR, Fang H, Fernandez GE, Sposto R, DeClerck YA. Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell Rep, 2018, 25(8): 2177-2191.e7.
[12]	Wang CL, Hao JJ, Wu LF, Pan BQ, Xu X, Cai Y, Wang MR, Jia XM . IGHMBP2 overexpression promotes cell migration and invasion in esophageal squamous carcinoma. Hereditas (Beijing), 2015,37(4):360-366.
	王春丽, 郝佳洁, 吴李飞, 潘蓓青, 徐昕, 蔡岩, 王明荣, 贾雪梅 . IGHMBP2过表达促进食管鳞癌细胞的侵袭和迁移. 遗传, 2015,37(4):360-366.
[13]	Liu Z, Yu SB, Ye ST, Shen ZM, Gao L, Han ZY, Zhang PP, Luo F, Chen S, Kang MQ . Keratin 17 activates AKT signalling and induces epithelial-mesenchymal transition in oesophageal squamous cell carcinoma. J Proteomics, 2020,211:103557.
[14]	Ma S, Lu CC, Yang LY, Wang JJ, Wang BS, Cai HQ, Hao JJ, Xu X, Cai Y, Zhang Y, Wang MR . ANXA2 promotes esophageal cancer progression by activating MYC- HIF1A-VEGF axis. J Exp Clin Cancer Res, 2018,37(1):183.
[15]	Dellas C, Loskutoff DJ . Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost, 2005,93(4):631-640.
[16]	Peng Y, Kajiyama H, Yuan H, Nakamura K, Yoshihara M, Yokoi A, Fujikake K, Yasui H, Yoshikawa N, Suzuki S, Senga T, Shibata K, Kikkawa F . PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor- promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Lett, 2019,442:181-192.
[17]	Ferroni P, Roselli M, Portarena I, Formica V, Riondino S, LA Farina F, Costarelli L, Melino A, Massimiani G, Cavaliere F, Palmirotta R, Guadagni F . Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer - relationship with clinical outcome. Anticancer Res, 2014,34(3):1153-1161.
[18]	Palmirotta R, Ferroni P, Savonarola A, Martini F, Ciatti F, Laudisi A, Sini V, Del Monte G, Guadagni F, Roselli M . Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res, 2009,124(4):403-408.
[19]	Che Y, Wang JN, Li Y, Lu ZL, Huang JB, Sun SG, Mao SS, Lei YY, Zang RC, Sun N, He J . Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance. Cell Death Dis, 2018,9(7):759.
[20]	Masuda T, Nakashima T, Namba M, Yamaguchi K, Sakamoto S, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Miyata Y, Hamada H, Okada M, Hattori N . Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts. J Cell Mol Med, 2019,23(4):2984-2994.
[21]	Fang HH, Jin J, Huang DD, Yang F, Guan XX . PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells. Cancer Sci, 2018,109(6):1949-1957.
[22]	Inoue M, Sawada T, Uchima Y, Kimura K, Nishihara T, Tanaka H, Yashiro M, Yamada N, Ohira M, Hirakawa K . Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncol Rep, 2005,14(6):1445-1451.
[23]	Geis T, Döring C, Popp R, Grossmann N, Fleming I, Hansmann ML, Dehne N, Brüne B . HIF-2alpha-dependent PAI-1 induction contributes to angiogenesis in hepatocellular carcinoma. Exp Cell Res, 2015,331(1):46-57.
[24]	Mashiko S, Kitatani K, Toyoshima M, Ichimura A, Dan T, Usui T, Ishibashi M, Shigeta S, Nagase S, Miyata T, Yaegashi N . Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biol Ther, 2015,16(2):253-260.
[25]	Pavón MA, Arroyo-Solera I, Téllez-Gabriel M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I, López-Pousa A, Mangues MA, Quer M, Barnadas A, Mangues R . Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. Oncotarget, 2015,6(30):29016-29033.
[26]	Humphries BA, Buschhaus JM, Chen YC, Haley HR, Qyli T, Chiang B, Shen N, Rajendran S, Cutter A, Cheng YH, Chen YT, Cong J, Spinosa PC, Yoon E, Luker KE, Luker GD . Plasminogen Activator Inhibitor 1 (PAI1) promotes actin cytoskeleton reorganization and glycolytic metabolism in triple-negative breast cancer. Mol Cancer Res, 2019. 17(5):1142-1154.
[27]	Herz J, Strickland DK . LRP: a multifunctional scavenger and signaling receptor. J Clin Invest, 2001,108(6):779-784.
[28]	Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q . Role of blood-brain barrier in Alzheimer's disease. J Alzheimers Dis, 2018,63(4):1223-1234.
[29]	Shinohara M, Tachibana M, Kanekiyo T, Bu G . Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. J Lipid Res, 2017,58(7):1267-1281.
[30]	Holtzman DM, Herz J, Bu GJ . Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med, 2012,2(3):a006312.
[31]	Gheysarzadeh A, Ansari A, Emami MH, Razavi AE, Mofid MR . Over-expression of low-density lipoprotein receptor- related Protein-1 is associated with poor prognosis and invasion in pancreatic ductal adenocarcinoma. Pancreatology, 2019,19(3):429-435.
[32]	Feng CC, Ding GX, Ding Q, Wen H . Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma. Biochem Biophys Res Commun, 2018,503(3):1537-1543.
[33]	Tian Y, Wang C, Chen S, Liu J, Fu Y, Luo Y . Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1. J Cell Sci, 2019,132(15).
[34]	Salama Y, Lin SY, Dhahri D, Hattori K, Heissig B . The fibrinolytic factor tPA drives LRP1-mediated melanoma growth and metastasis. FASEB J, 2019,33(3):3465-3480.

编辑推荐

Metrics

www.chinagene.cn
备案号：京ICP备09063187号-4
总访问:,今日访问:,当前在线:

PAI-1过表达促进食管鳞癌细胞的侵袭和迁移

PAI-1 overexpression promotes invasion and migration of esophageal squamous carcinoma cells

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 6

参考文献 34

相关文章 15

编辑推荐

Metrics

[1]	李芳,黄青芸,刘斯佳,郭忠信,熊欣欣,桂林,束会娟,黄绍明,谭国鹤,刘媛媛. Bmal1对小鼠胚胎期皮层神经元放射状迁移和轴突投射的影响[J]. 遗传, 2019, 41(6): 524-533.
[2]	胡伟澎, 李佑平, 张秀清. 基于迁移学习的MHC-I型抗原表位呈递预测[J]. 遗传, 2019, 41(11): 1041-1049.
[3]	沈秀莲, 逯宜超, 甲芝莲, 吴强. N-WASP通过polyPro和VCA结构域调控大脑皮层神经元迁移[J]. 遗传, 2018, 40(5): 390-401.
[4]	张俊玉,吕珊,牛慧敏,雷安民. 哺乳动物卵母细胞不对称分裂的研究进展[J]. 遗传, 2018, 40(4): 279-291.
[5]	杨阳露, 邹壮志, 袁方, 毛蓓蓓. YAP蛋白T425A位点突变对YAP功能的影响[J]. 遗传, 2017, 39(7): 675-682.
[6]	李迎迎,刘志广,王丽,袁园园,刘平,王林嵩. 血清miRNAs作为食管鳞癌新的生物标志物[J]. 遗传, 2015, 37(4): 315-320.
[7]	王春丽,郝佳洁,吴李飞,潘蓓青,徐昕,蔡岩,王明荣,贾雪梅. IGHMBP2过表达促进食管鳞癌细胞的侵袭和迁移[J]. 遗传, 2015, 37(4): 360-366.
[8]	陈良榉,杨明,陈艳,孙华钦,许文明. miR-15b在内皮细胞的功能及其与血管相关性疾病的关系[J]. 遗传, 2015, 37(2): 121-127.
[9]	谢树高, 谢银银, 张元亮,黄秋花. miR-145靶向调控DAB2对前列腺癌PC3细胞迁移和侵袭能力的影响[J]. 遗传, 2014, 36(1): 50-57.
[10]	张霆莫显明. 斑马鱼原肠胚细胞运动[J]. 遗传, 2013, 35(4): 441-448.
[11]	谢翔，胡建军，王贵学. 生物力学——胚胎血管系统发育研究新视野[J]. 遗传, 2012, 34(9): 1123-1132.
[12]	蒋焱熠，王明荣. 食管鳞癌染色体及基因组DNA畸变研究进展[J]. 遗传, 2012, 34(5): 519-525.
[13]	李艳，王晓钰，王丽京，徐涛，卢晓晔，蔡冬青，耿建国，杨雪松. PTEN抑制胚胎原肠胚形成期EMT的过程[J]. 遗传, 2011, 33(6): 613-619.
[14]	江明锋，张义正. 木质素降解条件下黄孢原毛平革菌lip基因转录调控序列的筛选与鉴定[J]. 遗传, 2005, 27(3): 435-441.
[15]	曲若竹，侯林，吕红丽，李海燕. 群体遗传结构中的基因流[J]. 遗传, 2004, 26(3): 0-382.